{
    "nctId": "NCT04106167",
    "briefTitle": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",
    "officialTitle": "Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy",
    "overallStatus": "TERMINATED",
    "conditions": "Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, EGFR Positive Solid Tumor, HER2-positive Breast Cancer, Hepatocellular Carcinoma, Small-cell Lung Cancer, Renal Cell Carcinoma, Pancreas Cancer, Melanoma, NSCLC, Urothelial Carcinoma, Cervical Cancer, Microsatellite Instability, Merkel Cell Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 20,
    "primaryOutcomeMeasure": "Overall Survival (OS) post-Infusion",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects who received an allogeneic, iPSC-derived NK cell in a Fate Therapeutics interventional study\n* Subjects who have provided Informed consent prior to their study participation\n\nExclusion Criteria:\n\n* Not Applicable",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}